Open AccessEffect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG
Author(s) -
Anna Zemczak,
Małgorzata Kołodziej,
Paweł Gut,
Leszek Królicki,
Beata KosKudła,
Grzegorz Kamiński,
Marek Ruchała,
Dariusz Pawlak,
Jolanta Kunikowska
Publication year - 2020
Publication title -
endokrynologia polska
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.413
H-Index - 27
eISSN - 2299-8306
pISSN - 0423-104X
DOI - 10.5603/ep.a2020.0014
Subject(s) - radionuclide therapy , medicine , neuroendocrine tumors , peptide receptor , nuclear medicine , progression free survival , somatostatin , somatostatin receptor , overall survival , gastroenterology , receptor
Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [¹⁸F]FDG PET/CT in predicting response, progression-free survival (PFS) and overall survival (OS) after tandem therapy [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE.